25 reviews of 80 billion chemical capsules! Eight more than 1 billion varieties of Kelun, Yangtze River, etc

According to data from minenet, the sales volume of terminal drug capsules in public medical institutions in China has increased steadily in recent years, reaching 82.802 billion yuan in 2018 As of October 25, 2019, there are 25 products that have been evaluated for capsules, 19 of which are exclusive, and 3 or more have been evaluated for Kelun, Yangzijiang, Hengrui, Qilu and other enterprises; in addition, 34 products are under evaluation, and 8 products, such as amoxicillin capsule, Cefalexin capsule and clindamycin hydrochloride capsule, are the most popular Sales of terminal chemical capsules in public medical institutions in China (unit: 10000 yuan) According to the data of minenet, in the terminal chemical drug market of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), the sales volume of capsule increased steadily, from 45.351 billion yuan in 2013 to 82.802 billion yuan in 2018 Among the top 20 brands, the sales of Novartis valsartan capsule, anstelai tacrolimus capsule, Shandong new era pharmaceutical's tegio capsule, Tianfang pharmaceutical's atorvastatin calcium capsule, and EBP pharmaceutical's butylphthalide soft capsule all exceeded 2 billion yuan Distribution channel pattern of terminal chemical capsule in public medical institutions of China in 2018 From the perspective of channel pattern, although the urban public hospitals are in the leading position, their market share is declining, accounting for only 61.80% in 2018; while the county-level public hospitals, urban community centers and township hospitals are gradually increasing Over evaluation of capsule Note: the terminal sales volume of China's public medical institutions in 2018 is the sales volume of generic capsules of over evaluated drugs As of October 25, there are 25 products (51 product specifications) that have passed or deemed to have passed the consistency evaluation, including 19 only one enterprise, 3 or more of which have passed the evaluation of Kelun, Yangzi River, Hengrui and other enterprises, and 8 of which have sold more than 1 billion capsules From the perspective of treatment categories, the most commonly used antibiotics, antineoplastic drugs, and systemic antiviral drugs have been evaluated It is worth mentioning that entecavir capsule, amoxicillin capsule, clindamycin hydrochloride capsule and Cefalexin capsule have been appraised by four enterprises Brand pattern of entecavir capsule in public medical institutions of China in 2018 In recent years, the sales volume of entecavir capsule in China's public hospitals increased rapidly, from 28.68 million yuan in 2013 to 706 million yuan in 2018 At present, there are five manufacturers, namely Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., Sichuan hisico Pharmaceutical Co., Ltd., Fujian guangshengtang Pharmaceutical Co., Ltd., Jiangxi Qingfeng Pharmaceutical Co., Ltd and Hainan Zhonghe Pharmaceutical Co., Ltd., while the first four enterprises have been evaluated, and Hainan Zhonghe Pharmaceutical Co., Ltd is under review and approval (in the drug review center) Top 20 brand pattern of amoxicillin capsule in public medical institutions of China in 2018 The competition of amoxicillin capsule is fierce, and there are more than 140 manufacturers In 2018, the sales volume of amoxicillin capsule reached 1.131 billion yuan at the end of China's public medical institutions, up 11.06% year on year At present, amoxicillin capsule has four enterprises, namely Sinopharm (Shijiazhuang), Hunan Kelun pharmaceutical, Zhejiang Jinhua Kangenbei biopharmaceutical and Zhuhai United pharmaceutical Top 20 brand pattern of clindamycin capsule in public medical institutions of China in 2018 In 2018, the sales volume of clindamycin in China's public medical institutions exceeded 3 billion yuan, with injection (70.48%) and tablet (23.14%) and capsule (1.06%) At present, the number of approval documents for clindamycin hydrochloride capsules has reached 151, and the number of manufacturers has exceeded 100 In terms of consistency evaluation, there are 4 enterprises and 6 enterprises with over evaluation of product planning, of which Sichuan Kelun Pharmaceutical Co., Ltd and Chongqing Yaoyou Pharmaceutical Co., Ltd each have two over evaluation of product planning Top 20 brand pattern of cephalexin capsule in public medical institutions of China in 2018 In 2018, the market share of Shandong Luoxin Pharmaceutical Group ranked first in the top 20 brand pattern of Cefalexin capsule in China's public medical institutions, accounting for nearly 30% In terms of consistency evaluation, at present, there are 4 enterprises and 7 products have been evaluated, including 3 in Hunan Kelun Pharmaceutical Co., Ltd., 2 in Shandong Luoxin Pharmaceutical Group, 1 in Yangzijiang Pharmaceutical Group and 1 in Shanghai Fuda Pharmaceutical Co., Ltd Products under review and more than 3 Enterprises